PCM
ALBO

Prelude Capital Management’s Albireo Pharma Inc ALBO Stock Holding History

Prelude Capital Management’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100
Closed -$3K – 2177
2020
Q3 		$3K Buy
+100
New +$2.91K ﹤0.01% 1648

Other funds holding ALBO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Prelude Capital Management's ALBO Position: Q1 2020 in Review

Prelude Capital Management sold out of Albireo Pharma Inc (ALBO) in Q1 2020, closing a stake of 340 shares — an estimated $9K sold.

Prelude Capital Management first reported a position in ALBO in Q4 2017 and held it in 9 quarters. The position peaked at $83K in Q1 2018. 69 funds tracked by Wall St. Rank hold ALBO as of Q1 2020.

  • Prelude Capital Management reported no remaining Albireo Pharma Inc position as of Q1 2020 after selling out during the quarter.
  • Prelude Capital Management sold 340 Albireo Pharma Inc shares in Q1 2020, an estimated $9K.
  • Prelude Capital Management first reported a position in Albireo Pharma Inc in Q4 2017 and held it in 9 quarters.
  • Prelude Capital Management's Albireo Pharma Inc position peaked at $83K in Q1 2018.
  • 69 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.